Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today (Update)

Update (4:11 p.m.): Updated with Monday market close information.

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) rose Monday after the company announced data on ponatinib, or Iclusig, from PACE and Phase 1 clinical trials.

The studies now indicate that with a median follow-up of 42.5 months for chronic-phase CML patients in the Phase 1 trial, Iclusig shows anti-leukemic activity in patients with limited treatment options.

The stock closed up 7.43%, or 48 cents, to $6.94. Ariad had a range of $6.74 to $7.50 for the day and holds a 52-week range of $2.15 to $23. More than 26 million shares changed hands, more than double the average volume of 10,324,300.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ARIA Price Chart

ARIA Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)